Assessing For Health Conditions Rapidly Using Saliva!
Who We Are
Baseline Global Inc. was established in November 2018 on a mission detect health related conditions e.g. Concussion, Alzheimer’s, Parkinson’s, PTSD, Depression, Autism, and Stroke with SALIVA. We have a patent-pending for the disposable device and the assessment is non-invasive, easy to use, accurate, affordable and delivers results in a timely way.
Baseline established Baseline Viral Diagnostics, Inc. (BVD) as a subsidiary company to focus on developing a unique COVID-19 detection device, which has a patent pending, along with specific biomarkers that detect COVID.
Unlike Antibody tests our device aims to detect positive results in asymptomatic users to identify an active infection. The non-invasive testing of individuals will enable “Safe Zone” assessments which can be applied to airports, stadiums, theatres, conferences, office buildings, hospitals, military, universities, schools, etc.
Biomarkers are proteins, nucleic acids or other molecular components that can be measured in saliva. These biomarkers can be collected easily with an initial assessment device (IAD) that Baseline is developing. This creates a non-invasive means for the initial assessment of health conditions rapidly.
According to MarketsandMarkets.com¹, the global market was valued at USD 21.40 Billion in 2016 and is expected to reach USD 38.13 Billion by 2022, at a CAGR of 10.0% during the forecast period.
Leveraging our non-invasive process to assess for early detection of health-related conditions utilizing custom saliva assays to produce an accurate result rapidly.
Baseline Global is a Biotech corporation which combines scientifically based salivary biomarker testing with a cutting-edge “lab on a stick” IAD.